Table 4

Number needed to treat (NNT) and number needed to harm (NNH) from the systematic reviews for Raynaud's phenomenon in systemic sclerosis (SSc)

Intervention[reference]Duration of interventionComparatorOutcomesRelative risk (95% CI)NNT/NNH (95% CI)
95% CI, 95% confidence interval, AEs, adverse events.
*Only point estimates of the NNHs were shown owing to the insignificant values of the RR (as shown in the 95% CI).
NNT
    Cyclofenil [24]6 monthsPlaceboUlcers improvement2.0 (0.56 to 7.12) 8.3*
    Iloprost [25]38 daysPlaceboGlobal improvement1.61 (0.96 to 2.71) 4.2*
    Iloprost [25]10 weeksPlaceboDigital ulcers healed8.12 (0.57 to 115.07) 1.2*
    Cisaprost [25]45 daysPlaceboGlobal improvement1.14 (0.54 to 2.4)16.1*
    Ketanserin [26]3–6 monthsPlaceboGlobal improvement3.07 (0.54 to 17.46) 2.3*
    Prazosin [27]6 weeksPlaceboGlobal improvement3.0 (0.15 to 59.89) 5.0*
NNH
    Cyclofenil [24]6 monthsPlaceboWithdrawals due to AEs1.5 (0.46 to 4.89)18.9*
    Iloprost [25]38 days–11 weeksPlaceboWith AEs2.05 (1.41 to 2.98) 2.1 (1.7 to 2.8)
    Cisaprost [25]45 daysPlaceboWith AEs1.2 (0.75 to 1.93) 8.0*
    Ketanserin [26]3 monthsPlaceboWithdrawals due to AEs2.71 (0.4 to 18.33) 2.2 (1.2 to 8.6)
    Prazosin [27]4 weeksPlaceboWithdrawals due to AEs4.17 (0.23 to 77.11) 5.5*